Eli Lilly: Overvaluation Is A Big Red Flag

Summary:

  • Eli Lilly’s stock is overvalued by around 27% despite its success in developing drugs for diabetes and obesity.
  • LLY has strong financial performance with steady revenue growth and profitability expansion.
  • The success of its drugs Mounjaro and Zepbound has led to a boost in revenue and positive growth prospects, but competition and market risks remain.

Эли Лилли и штаб-квартира компании World. Лилли производит лекарства и фармацевтические препараты.

jetcityimage/iStock Editorial via Getty Images

Investment thesis

Eli Lilly’s (NYSE:LLY) stock is on fire after the massive success of its new drugs aimed at treating diabetes and obesity. The company has a stellar track record of success and will likely


Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.


Leave a Reply

Your email address will not be published. Required fields are marked *